Evidence mapPaperPMID 30596170Full record

ArticleKidney international reports2019

Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins.

Markus Sällman Almén, Jonas Björk, Ulf Nyman, Veronica Lindström, Magnus Jonsson, Magnus Abrahamson, AnnaLotta Schiller Vestergren, Örjan Lindhe, Gary Franklin, Anders Christensson and 1 more

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 81 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. A lower eGFRRenal failure · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Markus Sällman AlménOlink Proteomics, Uppsala, Sweden.
Jonas BjörkDepartment of Occupational and Environmental Medicine, Lund University, Lund, Sweden.
Ulf NymanDepartment of Clinical Sciences, Lund University, Malmö, Sweden.
Veronica LindströmDepartment of Clinical Chemistry, Skåne University Hospital, Lund, Lund University, Sweden.
Magnus JonssonDepartment of Clinical Chemistry, Skåne University Hospital, Malmö, Sweden.
Magnus AbrahamsonDepartment of Laboratory Medicine, Lund University, Lund, Sweden.
AnnaLotta Schiller VestergrenOlink Proteomics, Uppsala, Sweden.
Örjan LindheOlink Proteomics, Uppsala, Sweden.
Gary FranklinOlink Proteomics, Uppsala, Sweden.
Anders ChristenssonDepartment of Nephrology, Skåne University Hospital, Malmö, Lund University, Sweden.
Anders GrubbDepartment of Clinical Chemistry, Skåne University Hospital, Lund, Lund University, Sweden.
Lund University · SEOlink Bioscience (Sweden) · SESkåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionShrunken pore syndrome (SPS), originally defined by cystatin C-based estimated glomerular filtration rate (eGFR

methodsFour patient cohorts were included: 1 cohort with normal mGFR without SPS, 1 with normal mGFR with SPS, 1 with reduced mGFR without SPS, and 1 with reduced mGFR with SPS. The plasma levels of 177 selected proteins were analyzed.

resultsDifferences in the levels of 30 proteins were specific for SPS; 31 differences were specific for patients with both SPS and reduced mGFR; and 27 were specific for reduced mGFR. Eighteen of the differences specific for SPS concerned proteins described as promoting, or being associated with, atherosclerosis. Twelve of the differences specific for patients with both SPS and reduced mGFR and 10 of the differences specific for reduced mGFR also concerned proteins described as promoting, or being associated with, atherosclerosis. Almost all (82 of 88) of the concentration differences represented increased levels. For SPS, but not for reduced mGFR, a correlation between protein size and increase in level was observed, with smaller proteins being associated with higher levels.

conclusionThe high mortality in shrunken pore syndrome might be caused by the accumulation of atherosclerosis-promoting proteins in this condition.

Indexed as

atherosclerosiscreatininecystatin CGFRkidneymortality

Identifiers

PMID30596170
PMCPMC6308389
OpenAlexW2889606776

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.